U.S. market Closed. Opens in 2 hours 10 minutes

CTXR | Citius Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.1600 - 0.2086
52 Week Range 0.1600 - 1.0700
Beta 1.68
Implied Volatility 307.05%
IV Rank 28.85%
Day's Volume 4,178,591
Average Volume 1,470,828
Shares Outstanding 180,725,000
Market Cap 30,705,178
Sector Healthcare
Industry Biotechnology
IPO Date 2014-10-02
Valuation
Profitability
Growth
Health
P/E Ratio -0.71
Forward P/E Ratio -11.79
EPS -0.24
1YR Price Target 6.00
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 22
Country USA
Website CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
CTXR's peers: XFOR, HOOK, MREO, GRTX, ABOS, FBIO, EYEN, OCUP, INZY, TERN, DAWN, BLRX, ARDX, LXRX, MCRB, IBRX, ITRM
*Chart delayed
Analyzing fundamentals for CTXR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see CTXR Fundamentals page.

Watching at CTXR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CTXR Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙